Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of B/HPIV3/S-6P Intranasal Vaccine for SARS-CoV-2
NCT06026514Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2023
- Primary completion
- Jan 2025
- Modality
- Live Vector Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of B/HPIV3/S-6P in Coronavirus Disease 2019 (COVID-19), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Frequency of vaccine-related solicited adverse events at 84 days, Frequency of vaccine-related unsolicited adverse events at 84 days and 3 more. Started Sep 2023; status: completed.
02
Drugs
B/HPIV3/S-6P
03
Conditions
Coronavirus Disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06026514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06026514.